A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

Name: A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
Published: 2013
License: Public Domain

Otsuka Pharmaceutical Development & Commercialization, Inc. · 2013

ClinicalTrials.gov · Datasets · License: Public Domain · 2013

Open Source ↗

alzheimer-s-disease dementia mental-disorder

agitation associated with, alzheimer's disease, alzheimer's type, mental disorder, nervous system diseases, opc-34712, brexpiprazole, dementia, cognitive disorders, agitation, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

Related documents